New Drugs and Regulation · eu
Psoriasis Treatment Brings IL-23 Blockade into the Oral Era: Icotyde Wins EMA Committee Backing
Four phase 3 trials showed that about half of patients achieved 90% improvement in skin lesions after 16 weeks of treatment; if approved by the European Commission, this oral peptide drug would add a new option for moderate-to-severe plaque psoriasis distinct from injectable biologics.
Patients with plaque psoriasis who require systemic therapy often have to weigh traditional oral drugs against injectable biologics, along with their respective efficacy and risks. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has now recommended approval of Icotyde (icotrokinra), giving a therapy that directly blocks the interleukin-23 (IL-23) receptor its first opportunity to enter the European Union market as an oral drug.
On July 23, the CHMP adopted a positive opinion recommending Icotyde for patients with moderate-to-severe plaque psoriasis who are eligible for systemic therapy. The indication covers adults and adolescents aged 12 years or older who weigh at least 40 kilograms; the applicant is Janssen-Cilag International N.V. The opinion must still be referred to the European Commission for a final marketing authorization decision and does not currently constitute formal approval.
The active ingredient in Icotyde is icotrokinra hydrochloride, and the drug is expected to be supplied as a 200-milligram film-coated tablet. Icotrokinra is a synthetic peptide that selectively binds to and antagonizes the IL-23 receptor, interrupting signaling closely associated with the inflammatory response in psoriasis. Existing therapies targeting the IL-23 pathway are mostly injectable antibodies. The drug’s most practical significance therefore lies in whether it can combine the convenience of oral administration with a high degree of skin clearance.
The evidence supporting the recommendation comes from four randomized phase 3 trials involving nearly 2,500 adults and adolescents. After 16 weeks of treatment, 50% to 57% of patients receiving icotrokinra achieved PASI 90, meaning an improvement of at least 90% from baseline in the Psoriasis Area and Severity Index; only 1% to 4% of patients in the placebo groups reached the same threshold. This indicates a clear effect on short-term skin lesion clearance, but the summary currently published by the EMA is not sufficient to fully compare responses among different populations, long-term maintenance of effect, or changes after treatment discontinuation.
Regarding safety, EMA data indicate that fungal infection was the most common adverse reaction. Because IL-23 is involved in immune regulation, infection risk and the safety of long-term use remain important considerations in clinical practice. The publicly available information at this stage also does not provide sufficiently complete data for direct comparisons of relative advantages and disadvantages with existing IL-23 biologics or other oral psoriasis drugs.
If the European Commission adopts the CHMP opinion, Icotyde’s value would lie not only in adding another psoriasis drug, but also in validating whether synthetic peptides can precisely target, through oral administration, an immune pathway previously occupied mainly by injectable biologics. However, the final label, monitoring requirements, and actual clinical positioning cannot be determined until formal authorization and more complete trial data are available.